In 2014 synlab services GmbH purchased INTERLAB GmbH central lab services – worldwide (INTERLAB). In September, INTERLAB merged with synlab Umweltinstitut GmbH, and consequently all documentation carries the synlab logo and will refer to the synlab pharma institute, Munich location, a division of synlab Umweltinstitut GmbH.
Please note that Dr. Hermann Schulz, Chief Executive Officer of INTERLAB until August 31st, 2015, will continue as a Legal Representative (“Prokurist”) of synlab Umweltinstitut GmbH. He will also head the synlab pharma institute as its Executive Vice President.
INTERLAB and synlab have been successfully cooperating since 2004. Hence, no impact on the day to day business or on the handling of study samples is to be expected. Our address, shipping logistics, and contractual terms shall not undergo any modifications. Although email addresses will switch form name@interlab.de to name@synlab.com your messages will automatically be re-routed.
As the new contractual partner, synlab Umweltinstitut GmbH shall overtake all duties and responsibilities of INTERLAB. Although invoices will be issued by synlab Umweltinstitut GmbH (using their tax ID: DE 195 993 312) the bank account at Deutsche Bank AG MuÌnchen will remain unchanged by the moment.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.